Journal francais d'ophtalmologie · 2025
[Socio-epidemiological, clinical and therapeutic profile of patients with advanced primary open-angle glaucoma in the ophthalmology department of CHU-campus, Lomé (Togo)].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amouzou D, Maneh N, Kawilitetou K S, Nonon-Saa K B, Bakoma B, Ayena K D, Balo K P
Аннотация
PURPOSE: The goal of this study was to determine the socio-epidemiological, clinical and therapeutic profile of patients with advanced POAG.
PATIENTS AND METHODS: Over a six-year period, we performed a retrospective cross-sectional analysis including patient interviews. The time frame for this study extended from January 1, 2013, to December 31, 2018. Patients with advanced POAG aged 18years and over who had been followed in the ophthalmology department of the CHU-Campus de Lomé for at least six months and who agreed to be interviewed were included.
RESULTS: One hundred two (102) patients met the inclusion criteria, with a mean age of 55.65±14.71years and a male predominance (56.86%). Monthly income was considered low in 58.82% of cases. Patients were educated in 85.29% of cases. Among the patients, 58.82% said they had been diagnosed with POAG after a decrease in visual acuity. The rate of monocular and binocular blindness was 21.78% and 22.77% respectively, after a mean progression time of 5.83 years. Triple therapy was used in 45% of cases.
CONCLUSION: POAG is a disease that inevitably progresses to blindness in the absence of adequate management. This study has enabled us to determine the profile of patients with advanced POAG at the CHU-Campus de Lomé. Knowledge of this profile might help to establish a new strategy for effective management of POAG.
PATIENTS AND METHODS: Over a six-year period, we performed a retrospective cross-sectional analysis including patient interviews. The time frame for this study extended from January 1, 2013, to December 31, 2018. Patients with advanced POAG aged 18years and over who had been followed in the ophthalmology department of the CHU-Campus de Lomé for at least six months and who agreed to be interviewed were included.
RESULTS: One hundred two (102) patients met the inclusion criteria, with a mean age of 55.65±14.71years and a male predominance (56.86%). Monthly income was considered low in 58.82% of cases. Patients were educated in 85.29% of cases. Among the patients, 58.82% said they had been diagnosed with POAG after a decrease in visual acuity. The rate of monocular and binocular blindness was 21.78% and 22.77% respectively, after a mean progression time of 5.83 years. Triple therapy was used in 45% of cases.
CONCLUSION: POAG is a disease that inevitably progresses to blindness in the absence of adequate management. This study has enabled us to determine the profile of patients with advanced POAG at the CHU-Campus de Lomé. Knowledge of this profile might help to establish a new strategy for effective management of POAG.